Literature DB >> 18048074

Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.

Linda S Wyatt1, Igor M Belyakov, Patricia L Earl, Jay A Berzofsky, Bernard Moss.   

Abstract

During propagation of modified vaccinia virus Ankara (MVA) encoding HIV 89.6 Env, a few viral foci stained very prominently. Virus cloned from such foci replicated to higher titers than the parent and displayed enhanced genetic stability on passage. Sequence analysis showed a single nucleotide deletion in the 89.6 env gene of the mutant that caused a frame shift and truncation of 115 amino acids from the cytoplasmic domain. The truncated Env was more highly expressed on the cell surface, induced higher antibody responses than the full-length Env, reacted with HIV neutralizing monoclonal antibodies and mediated CD4/co-receptor-dependent fusion. Intramuscular (i.m.), intradermal (i.d.) needleless, and intrarectal (i.r.) catheter inoculations gave comparable serum IgG responses. However, intraoral (i.o.) needleless injector route gave the highest IgA in lung washings and i.r. gave the highest IgA and IgG responses in fecal extracts. Induction of CTL responses in the spleens of individual mice as assayed by intracellular cytokine staining was similar with both the full-length and truncated Env constructs. Induction of acute and memory CTL in the spleens of mice immunized with the truncated Env construct by i.d., i.o., and i.r. routes was comparable and higher than by the i.m. route, but only the i.r. route induced CTL in the gut-associated lymphoid tissue. Thus, truncation of Env enhanced genetic stability as well as serum and mucosal antibody responses, suggesting the desirability of a similar modification in MVA-based candidate HIV vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18048074      PMCID: PMC2289778          DOI: 10.1016/j.virol.2007.10.033

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  63 in total

1.  Vaccination of mice and nonhuman primates using HIV-gene-containing DNA.

Authors:  M A Liu; Y Yasutomi; M E Davies; H C Perry; D C Freed; N L Letvin; J W Shiver
Journal:  Antibiot Chemother (1971)       Date:  1996

Review 2.  The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses.

Authors:  G Antoine; F Scheiflinger; F Dorner; F G Falkner
Journal:  Virology       Date:  1998-05-10       Impact factor: 3.616

3.  Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.

Authors:  I M Belyakov; L S Wyatt; J D Ahlers; P Earl; C D Pendleton; B L Kelsall; W Strober; B Moss; J A Berzofsky
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Epitope map of human immunodeficiency virus type 1 gp41 derived from 47 monoclonal antibodies produced by immunization with oligomeric envelope protein.

Authors:  P L Earl; C C Broder; R W Doms; B Moss
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection.

Authors:  R S Veazey; M DeMaria; L V Chalifoux; D E Shvetz; D R Pauley; H L Knight; M Rosenzweig; R P Johnson; R C Desrosiers; A A Lackner
Journal:  Science       Date:  1998-04-17       Impact factor: 47.728

6.  Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.

Authors:  L S Wyatt; S T Shors; B R Murphy; B Moss
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

7.  Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.

Authors:  L S Wyatt; S S Whitehead; K A Venanzi; B R Murphy; B Moss
Journal:  Vaccine       Date:  1999-10-14       Impact factor: 3.641

8.  The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys.

Authors:  A P Durbin; L S Wyatt; J Siew; B Moss; B R Murphy
Journal:  Vaccine       Date:  1998-08       Impact factor: 3.641

9.  Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1.

Authors:  A Trkola; M Purtscher; T Muster; C Ballaun; A Buchacher; N Sullivan; K Srinivasan; J Sodroski; J P Moore; H Katinger
Journal:  J Virol       Date:  1996-02       Impact factor: 5.103

10.  Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge.

Authors:  I M Belyakov; M A Derby; J D Ahlers; B L Kelsall; P Earl; B Moss; W Strober; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-17       Impact factor: 11.205

View more
  31 in total

1.  Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Authors:  Paul A Goepfert; Marnie L Elizaga; Alicia Sato; Li Qin; Massimo Cardinali; Christine M Hay; John Hural; Stephen C DeRosa; Olivier D DeFawe; Georgia D Tomaras; David C Montefiori; Yongxian Xu; Lilin Lai; Spyros A Kalams; Lindsey R Baden; Sharon E Frey; William A Blattner; Linda S Wyatt; Bernard Moss; Harriet L Robinson
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

2.  Role of cell signaling in poxvirus-mediated foreign gene expression in mammalian cells.

Authors:  Ningjie Hu; Richard Yu; Cecilia Shikuma; Bruce Shiramizu; Mario A Ostrwoski; Qigui Yu
Journal:  Vaccine       Date:  2009-03-10       Impact factor: 3.641

3.  Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.

Authors:  Edwin R Manuel; Zhongde Wang; Zhongqi Li; Corinna La Rosa; Wendi Zhou; Don J Diamond
Journal:  Virology       Date:  2010-05-14       Impact factor: 3.616

4.  Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.

Authors:  Anne-Marie C Andersson; Emeline Ragonnaud; Kelly E Seaton; Sheetal Sawant; Antonella Folgori; Stefano Colloca; Celia Labranche; David C Montefiori; Georgia D Tomaras; Peter J Holst
Journal:  Vaccine       Date:  2016-09-12       Impact factor: 3.641

5.  Novel vaccine regimen elicits strong airway immune responses and control of respiratory syncytial virus in nonhuman primates.

Authors:  Thomas Grunwald; Matthias Tenbusch; Reiner Schulte; Katharina Raue; Hans Wolf; Drew Hannaman; Rik L de Swart; Klaus Uberla; Christiane Stahl-Hennig
Journal:  J Virol       Date:  2014-01-22       Impact factor: 5.103

6.  Prevention of infection by a granulocyte-macrophage colony-stimulating factor co-expressing DNA/modified vaccinia Ankara simian immunodeficiency virus vaccine.

Authors:  Lilin Lai; Suefen Kwa; Pamela A Kozlowski; David C Montefiori; Guido Ferrari; Welkin E Johnson; Vanessa Hirsch; Francois Villinger; Lakshmi Chennareddi; Patricia L Earl; Bernard Moss; Rama Rao Amara; Harriet L Robinson
Journal:  J Infect Dis       Date:  2011-07-01       Impact factor: 5.226

7.  The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 protein.

Authors:  Kaori Shinoda; Linda S Wyatt; Bernard Moss
Journal:  Virology       Date:  2010-06-17       Impact factor: 3.616

8.  Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Authors:  Paul A Goepfert; Marnie L Elizaga; Kelly Seaton; Georgia D Tomaras; David C Montefiori; Alicia Sato; John Hural; Stephen C DeRosa; Spyros A Kalams; M Juliana McElrath; Michael C Keefer; Lindsey R Baden; Javier R Lama; Jorge Sanchez; Mark J Mulligan; Susan P Buchbinder; Scott M Hammer; Beryl A Koblin; Michael Pensiero; Chris Butler; Bernard Moss; Harriet L Robinson
Journal:  J Infect Dis       Date:  2014-01-07       Impact factor: 5.226

9.  Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.

Authors:  Linda S Wyatt; Patricia L Earl; Jennifer Vogt; Leigh Anne Eller; Dev Chandran; Jinyan Liu; Harriet L Robinson; Bernard Moss
Journal:  Vaccine       Date:  2007-12-03       Impact factor: 3.641

10.  Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines.

Authors:  Zhongde Wang; Joy Martinez; Wendi Zhou; Corinna La Rosa; Tumul Srivastava; Anindya Dasgupta; Ravindra Rawal; Zhongqui Li; William J Britt; Don Diamond
Journal:  Vaccine       Date:  2009-12-05       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.